145 related articles for article (PubMed ID: 28115821)
21. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
Hollander P; Raslova K; Skjøth TV; Råstam J; Liutkus JF
Diabetes Obes Metab; 2011 Mar; 13(3):268-75. PubMed ID: 21205123
[TBL] [Abstract][Full Text] [Related]
22. [Effectiveness and safety of initiation of once-daily insulin detemir in Chinese patients with type 2 diabetes previously treated with different quantities of oral anti-diabetic drugs: subgroup analysis of the Chinese SOLVE™ Study].
Pan C; Ji L; Lu J; Yang W; Zhou Z;
Zhonghua Nei Ke Za Zhi; 2015 Jul; 54(7):612-7. PubMed ID: 26359024
[TBL] [Abstract][Full Text] [Related]
23. Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study.
Malek R; Arbouche Z; Dahaoui A; Bachaoui M
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S15-26. PubMed ID: 23958568
[TBL] [Abstract][Full Text] [Related]
24. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Hermansen K; Davies M; Derezinski T; Martinez Ravn G; Clauson P; Home P
Diabetes Care; 2006 Jun; 29(6):1269-74. PubMed ID: 16732007
[TBL] [Abstract][Full Text] [Related]
25. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
[TBL] [Abstract][Full Text] [Related]
26. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
Garber AJ; Clauson P; Pedersen CB; Kølendorf K
J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
[TBL] [Abstract][Full Text] [Related]
27. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
Khunti K; Caputo S; Damci T; Dzida GJ; Ji Q; Kaiser M; Karnieli E; Liebl A; Ligthelm RJ; Nazeri A; Orozco-Beltran D; Pan C; Ross SA; Svendsen AL; Vora J; Yale JF; Meneghini LF;
Diabetes Obes Metab; 2012 Dec; 14(12):1129-36. PubMed ID: 22830956
[TBL] [Abstract][Full Text] [Related]
28. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
[TBL] [Abstract][Full Text] [Related]
29. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
[TBL] [Abstract][Full Text] [Related]
30. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
[TBL] [Abstract][Full Text] [Related]
31. Addition of insulin aspart with basal insulin is associated with improved glycemic control in Indian patients with uncontrolled type 2 diabetes mellitus: the A1chieve observational study.
Banerjee S; Maji D; Baruah M
J Assoc Physicians India; 2013 Jan; 61(1 Suppl):24-7. PubMed ID: 24482984
[TBL] [Abstract][Full Text] [Related]
32. Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.
Chraibi A; Ajdi F; Belkhadir J; El Ansari N; Marouan F; Farouqi A
Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S27-36. PubMed ID: 23958569
[TBL] [Abstract][Full Text] [Related]
33. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
34. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
Pan C; Han P; Ji L; Ji Q; Lu J; Lin J; Liu J; Su B; Shi J; Wang P
J Diabetes; 2015 Mar; 7(2):222-30. PubMed ID: 24909984
[TBL] [Abstract][Full Text] [Related]
35. Clinical experience with insulin detemir: results from the Indonesian cohort of the international A₁chieve study.
Soewondo P; Kshanti IA; Pramono RB; Langi YA; Dalem-Pemayun TG
Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S47-53. PubMed ID: 23647719
[TBL] [Abstract][Full Text] [Related]
36. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
[TBL] [Abstract][Full Text] [Related]
37. Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study.
Bhargava A; Chan V; Kimball ES; Oyer DS
Drugs Aging; 2016 Feb; 33(2):135-41. PubMed ID: 26833348
[TBL] [Abstract][Full Text] [Related]
38. Effect of insulin detemir dose frequency on clinical outcomes in patients with diabetes in PREDICTIVE.
Fontaine P; Gin H; Pinget M; Thivolet C; Hanaire H; Robert JJ; Marre M; Venkatanarasimhachar S
Adv Ther; 2009 May; 26(5):535-51. PubMed ID: 19513632
[TBL] [Abstract][Full Text] [Related]
39. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L;
Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
